Novo Nordisk A/S Re-initiates Phase 3 Development of Liraglutide for Obesity

BAGSVAERD, DENMARK--(Marketwire - 06/22/10) - Novo Nordisk today announced the decision to re-initiate the global phase 3 development programme of liraglutide for the treatment of obesity.

Source: Novo Nordisk A/S via Thomson Reuters ONE